Service Act, as added by section 5, in compari-
son to other health care providers, increased 
early detection of cancer and quality of cancer 
care for such women; and 
(C) 
recommendations 
for 
increasing 
screening rates for such women who are less 
likely to be screened or treated for breast, cer-
vical, ovarian, and other gynecological cancers; 
(4) an analysis of how structural racism im-
pacts access to cancer screening services, correlates 
to the development of breast, cervical, ovarian, and 
other gynecological cancers, and exacerbates health 
care disparities for African-American, Hispanic and 
Latina women, and other women of color; 
(5) in consultation with the Comptroller Gen-
eral of the United States, estimated Federal savings 
achieved through early detection of breast and 
gynecologic cancers; 
(6) recommendations by the Secretary with re-
spect to the need for continued increased access to 
women’s health care providers, such as the entities 
described in section 317P–2(c) of the Public Health 
Service Act, as added by section 5, who provide pre-
ventive care, including life-saving cancer screenings; 
and 
VerDate Sep 11 2014 
19:45 Dec 30, 2024
Jkt 059200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6201
E:\BILLS\H10287.IH
H10287
ssavage on LAPJG3WLY3PROD with BILLS
(7) an evaluation of the demonstration project 
on co-testing for human papillomavirus and cervical 
cancer under section 317P–3 of the Public Health 
Service Act, as added by section 7, including the re-
sults of the demonstration project and a rec-
ommendation on whether expansion of the co-testing 
model described in such section 317P–3 would be 
advised in order to promote early intervention, 
screening uptake, and reduce cervical cancer deaths 
and racial and ethnic disparities. 
SEC. 7. DEMONSTRATION PROJECT ON CO-TESTING FOR 
HUMAN PAPILLOMAVIRUS AND CERVICAL 
CANCER. 
Part B of title III of the Public Health Service Act 
(42 U.S.C. 243 et seq.), as amended by section 5, is fur-
ther amended by inserting after section 317P–2 the fol-
lowing: 
‘‘SEC. 317P–3. DEMONSTRATION PROJECT ON CO-TESTING 
FOR HUMAN PAPILLOMAVIRUS AND CER-
VICAL CANCER. 
‘‘(a) IN GENERAL.—The Secretary, in consultation 
with the Director of the Centers for Disease Control and 
Prevention and the Administrator of the Health Resources 
and Services Administration, as appropriate, shall estab-
lish a 2-year demonstration project on increasing the cer-
VerDate Sep 11 2014 
19:45 Dec 30, 2024
Jkt 059200
PO 00000
Frm 00012
Fmt 6652
Sfmt 6201
E:\BILLS\H10287.IH
H10287
ssavage on LAPJG3WLY3PROD with BILLS
vical cancer screening co-testing of human papillomavirus 
and cervical cytology (commonly referred to as ‘Pap tests’) 
to develop models for increasing the rates of co-testing 
among women with disproportionate rates of cervical can-
cer, including African-American and Hispanic and Latina 
women. 
‘‘(b) USE OF FUNDS.—Entities receiving an award 
under this section shall use such award to— 
‘‘(1) increase access to co-testing of human 
papillomavirus testing and cervical cancer among pa-
tients with disproportionate rates of cervical cytol-
ogy, including African-American and Hispanic and 
Latina women; 
‘‘(2) support culturally and linguistically appro-
priate delivery models to such patients, including 
through the provision of interpretation services; or 
‘‘(3) provide other services to improve health 
outcomes with respect to such patients. 
‘‘(c) PRIORITIZATION.—In making awards under this 
section, the Secretary shall give priority to eligible entities 
serving low-income, uninsured, or medically underserved 
populations (as defined in section 330(b)(3)) or popu-
lations with historically low rates of such co-testing, such 
as older women. 
VerDate Sep 11 2014 
19:45 Dec 30, 2024
Jkt 059200
PO 00000
Frm 00013
Fmt 6652
Sfmt 6201
E:\BILLS\H10287.IH
H10287
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(d) ELIGIBLE ENTITIES.—To be eligible to receive 
a grant under this section, an entity shall be an entity 
described in section 317P–2(c).’’. 
Æ 
VerDate Sep 11 2014 
19:45 Dec 30, 2024
Jkt 059200
PO 00000
Frm 00014
Fmt 6652
Sfmt 6301
E:\BILLS\H10287.IH
H10287
ssavage on LAPJG3WLY3PROD with BILLS